Comment
Author: Admin | 2025-04-28
Getty ImagesMerck reported 4% revenue growth in the third quarter, including 17% sales growth from leading cancer drug Keytruda. The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The pharma industry is expected to grow 4.7% annually, reaching $1.4 trillion by 2029. Not only are pharmaceutical stocks excellent defensive investments in an uncertain economy, some pharma stocks pay sizable dividends that can be a source of steady income and help offset the impact of inflation. Here are seven pharmaceutical stocks to buy with dividends of at least 2%, according to Argus: Stock Upside Potential* Forward Dividend Yield Johnson & Johnson (ticker: JNJ) 26.1% 3.3% AbbVie Inc. (ABBV) 28.9% 3.8% Merck & Co. Inc. (MRK) 29.3% 3.3% AstraZeneca PLC (AZN) 23.9% 2.1% Amgen Inc. (AMGN) 29.5% 3.4% Sanofi (SNY) 15.4% 3.9% Gilead Sciences Inc. (GILD) 7.6% 3.3% *As of Jan. 23 close. Based on Argus 12-month price targets.Johnson & Johnson (JNJ)Johnson & Johnson is a global leader in the pharmaceutical, medical device and consumer health care products industries. Its key products include anti-inflammation drug Stelara, multiple myeloma and light chain amyloidosis drug Darzalex, and headache and pain relief drug Tylenol. Analyst David Toung says Johnson & Johnson offers investors an attractive balance of consistent pharmaceutical profits and highly innovative, high-growth medical technology. Toung says Johnson & Johnson also has a strong slate of upcoming product launches, including new pulse field ablation products for electrophysiology expected in early 2025. Argus has a "buy" rating and $185 price target for JNJ stock, which closed at $146.64 on Jan. 23.Dividend yield: 3.3%AbbVie Inc. (ABBV)AbbVie is a global pharmaceutical company. Its key drugs include Humira for treating rheumatoid arthritis, psoriasis, Crohn's disease and other conditions, and Skyrizi for treating plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Analyst Jasper Hellweg recently upgraded AbbVie's stock, citing impressive growth from Skyrizi and inflammation treatment Rinvoq. In the third quarter, AbbVie reported 52% growth in Skyrizi sales and 47% growth in Rinvoq sales. In fact,
Add Comment